The significant prevalence of chronic gastritis and/or duodenitis among children and adolescents, the ability of H. pylori to induce serious complications lead to the importance of effective anti-helicobacter therapy. The aim of the work was to determine the rationality of prescribed drugs and the expediency of financial expenses for pharmacotherapy of chronic gastritis and/or duodenitis associated with H. pylori and gastro-esophageal reflux disease based on the results of a retrospective clinical and economic analysis of medical prescriptions in Dnipro. The material for the study were the 92 prescription sheets (form No. 003-4/y) of stationary patients aged 5–17 years with a diagnosis of chronic gastritis and/or duodenitis associated with H. pylori and gastro-esophageal reflux disease undergoing treatment at the Dnipropetrovsk Children's City Clinical Hospital № 6 for the period 2012–2017. Analysis of the prescriptions frequency, their ranking for cost and importance for the treatment were carried out using pharmacoeconomic methods: ABC-, VEN-, frequency analysis and integrated frequency/ABC/VEN analysis. Frequency analysis of treatment regimens showed that only 47.8% of patients were prescribed a «gold standard» of treatment, while 52.2% of patients had medical prescriptions that did not comply with the national treatment protocols adopted by the Ministry of Health of Ukraine. It was found that in the structure of medical prescriptions for the treatment of chronic gastritis and/or duodenitis associated with H. pylori and GERD, there was excessive use of non-essential drugs «N» (43.9%), which were prescribed almost in the same volume as vital drugs «V» (56.1%). According to the ABC-analysis, it was established, that the main financial resources were spent on the medicines of six groups: dietary supplements for normalization and maintenance of normal intestinal microflora, omeprazole, mozapride, clarithromycin, domperidone and amoxicillin. It was found, that on average one patient was prescribed 6.6 preparations worth 722.42 UAH. It can be concluded that the main funds was not spent on the necessary and important medicines for the treatment of the studied nosologies.

Introduction: On the pharmaceutical market of Ukraine, there are six international non-proprietary names of proton pump inhibitors (PPIs) – Omeprazole, Pantoprazole, Lansoprazole, Rabeprazole, Esomeprazole, Dexlansoprazole, which differ in a number of pharmacokinetic and pharmacodynamic parameters, safety profile, range of dosage forms and their cost. The aim: To investigate the competitiveness of proton pump inhibitors registered in Ukraine by comparing the parameters of their quality properties using the method of qualimetric analysis. Materials and methods: Qualimetric analysis is based on the deductive-axiomatic approach, which allows quantifying the qualitative properties of drugs and determining the degree of competitiveness of each of them in the pharmaceutical market of Ukraine. The qualitative properties of PPIs in terms of consumer are efficacy, safety, convenience of use and cost. The subject of the study was 133 trademarks of PPIs registered in Ukraine. Results: The highest qualimetric values were obtained by omeprazole (Kk = 0.73) and its S-isomer esomeprazole (Kk = 0.66). Pantoprazole was inferior to them to a certain extent (Kk = 0.64). Lansoprazole (Kk = 0.53), rabeprazole (Kk = 0.50) and dexlansoprazole (Kk = 0.44) had the lowest values of the quality indices. Conclusions: According to the results of the study of the PPIs’ competitiveness for parameters characterizing efficacy, safety, convenience of use and cost, assessed by qualimetric analysis, it has been established that the most completely and qualitatively satisfying consumer’s needs are omeprazole and its S-isomer, esomeprazole.